Session Chair Profile
Ph.D., Chief Business & Product Development Officer, Genomic Health
Biography
Over the last 25 years, Frederic Pla has built and launched global businesses in medical diagnostics and devices, life sciences, and healthcare information technology, consistently delivering high growth and profitability through a blend of product innovation, strategic acquisitions, and successful turnarounds. Before joining Genomic Health, Frederic was the Vice President, Corporate Business Development, for Life Technologies, until its acquisition by Thermo Fisher. Frederic led many of the company’s internal and external growth initiatives, adding nearly $2.5 billion in yearly revenue through 30 acquisitions across areas such as diagnostics, food safety and animal health, bioinformatics and life sciences tools. Prior to joining Life Technologies, Fred held global managerial positions of increasing responsibilities at GE Healthcare, where he contributed to the formation and growth of GE’s $2.4 billion Healthcare IT business. Fred started his career in R&D, first at the NASA Glenn Research Center.
Session Abstract – PMWC 2017 Silicon Valley
Session Synopsis: Liquid biopsies have the potential to bring precision medicine into the care of cancer patients for whom access to tissue is challenging. However, detecting tumor-specific DNA variants in blood samples presents challenges to the analytical validity and operational efficiency of these tests. This session will explore how leaders in the field are addressing these challenges to bring liquid biopsy to clinicians and their patients.
